| Name | Title | Contact Details |
|---|
CompleteCare is a North Little Rock, AR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
MCS-Medical Consulting and Solutions is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
U.S. ELECTRONICS INC is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
EnteroMedics® Inc. is the developer of vBloc® neurometabolic therapy, delivered by a pacemaker-like device called the Maestro® Rechargeable System, a first-in-class weight loss treatment for obesity and obesity related risk factors, such as high blood pressure or high cholesterol levels. vBloc Therapy is a non-anatomy altering or restricting, reversible therapy that allows patients to safely lose weight by helping patients feel less hungry, reduce the amount of food eaten at a meal, and feel full longer in between meals. vBloc Therapy is now approved by the Food and Drug Administration for weight loss in adults with a BMI of 40 to 45 kg/m2 or a BMI of 35 to 39.9 kg/m2 with a related health condition such as high blood pressure or high cholesterol levels.* *Individuals should have first tried to lose weight by diet and exercise in a supervised program within the last 5 years before receiving the Maestro System.
OXiGENE is a biopharmaceutical company developing new and improved therapeutics that have the potential to deliver significant medical benefits to patients with cancer and serious medical conditions. Our primary focus is developing first-in-class anti-vascular drugs referred to as vascular disrupting agents (VDAs). Our lead compound in clinical development is fosbretabulin. VDAs are a new and highly differentiated class of anti-vascular drug that target existing tumor vasculature, leading to extensive tumor cell death. VDAs target the tumor vasculature rather than the tumor cells and therefore have broad potential therapeutic utility in cancer. Because VDAs act differently than anti-angiogenic drugs or cytotoxic chemotherapy drugs, VDAs are potentially complementary with anti-angiogenic drugs and chemotherapeutic agents. OXiGENE has ongoing VDA drug development programs and is committed to advancing the science of VDAs and their potential as innovative therapies to address unmet medical needs.